IDEXX Laboratories and certain affiliates entered into Amendment No. 9 to the U.S. supply agreement and Amendment No. 7 to the European supply agreement, effective as of October 31, 2024, the company said.

1. 01

   IDEXX Laboratories and certain affiliates entered into Amendment No. 9 to the U.S. supply agreement and Amendment No. 7 to the European supply agreement, effective as of October 31, 2024, the company said.

2. 02

   The company said the amendments cover its agreement between IDEXX Operations, Inc. and Ortho-Clinical Diagnostics, Inc. and its agreement between IDEXX B.V. and Ortho, both effective as of October 16, 2003.

3. 03

   The company said the U.S. and European supply agreements provide for Ortho to supply dry slides for IDEXX's veterinary chemistry analyzers.

4. 04

   The company said the amendments extend the expiration dates of the existing U.S. and European supply agreements to the end of 2044 and modify pricing, including volume tiers and related pricing over the contract terms.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.